3.1 Descriptive analysis
After data cleaning, 17,710,899 reports in the FAERS database were of
use. Overall, from January 2004 to March 2022, there were 3694 reports
listing voriconazole were identified as PS, the number of hepatic
dysfunction events was 646 (17.48%). The clinical characteristics of
patients with voriconazole induced hepatic dysfunction were described inTable 1 . The hepatic disorders associated with voriconazole
were slightly higher in male than in female (56.50% vs. 33.90%,
P<0.05), and 27.40% of them are elderly patients (≥65 years old). The
fatality rate of the reported hepatic disorders was 9.75%, which is
lower than non-hepatic disorders.
The median time to event of the hepatic dysfunction events was 8 (IQR
2-28) days, and 62.20% of patients developed hepatic dysfunction in 15
days of voriconazole use (Fig. 1 ).